Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2008

View Archived Issues

Eisai refocuses E-2007 program

Advanced Life Sciences plans cethromycin NDA submission

Recent patents cover new treatments for musculoskeletal and connective tissue disorders

Mesoblast expands phase II spinal fusion trial and accelerates plans for phase III

CVX-045 active alone and with chemotherapy in cancer models

EP-128265 induces apoptosis in vivo

Symbollon reports results of IoGen phase III trial in fibrocystic breast-related pain

Takeda to acquire Millennium

Encouraging preliminary results reported for Ad35 tuberculosis vaccine

Preclinical data supports use of AAV vectors to deliver siRNA

ThromboGenics completes enrollment in phase II trial of microplasmin for acute stroke

Napo reports successful results from Glenmark's phase II trial of crofelemer in diarrhea

Fatty acid amide hydrolase inhibitor ameliorates pain in preclinical study

Glenmark completes preclinical development for GBR-500, plans to submit an IND application

TL-1892 active in paclitaxel- and docetaxel-resistant tumor models

Manhattan completes enrollment in phase IIa clinical study of topical PTH (1-34) in psoriasis

Z(Abeta3) binds to amyloid-beta(1-40), inhibits amyloid formation

Haemacure reports positive results from preclinical study of fibrin sealant Hemaseel HMN

SMT-D002 suppresses sebum levels by 90% in repeat-dose trial

Rituxan fails to meet primary endpoint in primary-progressive MS study

AtheroGenics reports interim results from phase III AGI-1067 diabetes trial

Oramed initiates phase IIa clinical trial for oral insulin

Kosan initiates phase II epothilone KOS-1584 trial in non-small cell lung cancer

Recent Janssen patents describe new treatment options for cardiovascular disorders

Recent Roche patent imparts new anti-HIV agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...